The pharmaceutical industry is built on a foundation of reliable chemical building blocks. Among these, 6-Amino-5-bromoquinoxaline, identified by its CAS number 50358-63-9, stands out as a crucial intermediate, particularly for the synthesis of Brimonidine Tartrate. This compound's precise chemical structure and high purity are non-negotiable for manufacturers aiming to produce effective and safe medications. This guide focuses on what pharmaceutical developers need to know when sourcing this vital chemical, from its intrinsic properties to the market landscape.

At its core, 6-Amino-5-bromoquinoxaline is valued for its specific molecular configuration and the quality it brings to synthesis processes. It is typically supplied as a light yellow to brown powder, with a melting point range of 151-153°C. The critical specification for any pharmaceutical application is its purity, which is consistently reported to be greater than 99.0% via HPLC. This high level of purity is essential to prevent unwanted side reactions and ensure the final drug product meets regulatory standards. When searching for 6-Amino-5-bromoquinoxaline suppliers, developers must prioritize those who can provide detailed Certificates of Analysis (CoA) that confirm these specifications.

The primary driver for the demand for 6-Amino-5-bromoquinoxaline is its indispensable role in the production of Brimonidine Tartrate. This medication is a cornerstone in the treatment of glaucoma, a condition that affects millions globally. The synthesis pathway for Brimonidine Tartrate relies on the specific reactivity of the 6-Amino-5-bromoquinoxaline molecule. Consequently, a consistent and dependable supply of this intermediate is vital for ensuring that patients have access to their prescribed treatments. Companies looking to purchase 6-Amino-5-bromoquinoxaline often seek out manufacturers with established track records and robust quality management systems.

The market for pharmaceutical intermediates is global, with many manufacturers based in China offering competitive pricing and significant production capacities. However, quality assurance remains the most critical factor. Pharmaceutical developers should investigate the manufacturing processes, quality control measures, and regulatory compliance of potential 6-Amino-5-bromoquinoxaline manufacturers. Beyond its use in Brimonidine Tartrate, the compound's potential as a versatile building block in medicinal chemistry means it is also valuable for research into new therapeutic agents. This broadens its appeal and reinforces the need for reliable sourcing partners.

In conclusion, securing high-quality 6-Amino-5-bromoquinoxaline (CAS: 50358-63-9) is a strategic decision for any pharmaceutical development project. By focusing on purity, supplier reliability, and understanding its critical role in applications like Brimonidine Tartrate synthesis, developers can build a strong foundation for their manufacturing processes and contribute to the availability of essential medicines.